good news
Ocugen has added ~6.5% in the pre-market after its partner Bharat Biotech was granted the Emergency Use Listing (EUL) for its COVID-19 vaccine by the World Health Organization (WHO) on Wednesday.
Ocugen has partnered with Bharat Biotech to co-develop the vaccine for the U.S. market. Last week, the company said it requested FDA clearance to start a U.S.-based late-stage study for COVAXIN.
精彩评论